Pharmaceuticals - Community Register

  

Community register of veterinary medicinal products


AUTHORISED  

Product information

Invented name: Purevax RC   
Auth. number : EU/2/04/051
INN : Not available
ATC: Anatomical main group: QI - Immunologicals
Therapeutic subgroup: QI06 - Immunologicals for felidae
Pharmacological subgroup: QI06A - Cat
Chemical subgroup: QI06AX - Other immunologicals
Chemical substance: QI06AX - Other immunologicals
(See WHO ATCvet Index)
Indication: Active immunisation of cats aged 8 weeks and older:
- against feline viral rhinotracheitis to reduce clinical signs,
- against calicivirus infection to reduce clinical signs and excretion.
Onsets of immunity have been demonstrated 1week after primary vaccination course for rhinotracheitis and calicivirus components.
The duration of immunity is 1 year after the last (re-)vaccination.
Marketing Authorisation Holder: Merial
29 avenue Tony Garnier, F-69007 Lyon, France

  EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which continues to be available in the Community Register.

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
25/02/2005 Centralised - Authorisation EMEA/V/C/91 (2005)474 of 23/02/2005
18/07/2005 Centralised - Variation EMEA/V/C/91/II/1
25/01/2008 Centralised - Variation EMEA/V/C/91/II/2, 3, 4 (2008)332 of 22/01/2008
22/09/2008 Centralised - Variation EMEA/V/C/91/II/5
20/02/2009 Centralised - Variation EMEA/V/C/91/II/6 (2009)1182 of 17/02/2009
24/04/2009 Corrigendum (2009)3096 of 21/04/2009
19/01/2010 Centralised - Renewal EMEA/V/C/91/R/7 (2010)189 of 15/01/2010
30/01/2013 Centralised - Variation EMEA/V/C/91/WS/325/G (2013)526 of 28/01/2013